Essential Strategies for Securing a Certificate of Pharmaceutical Product for EU Export Markets
The Certificate of Pharmaceutical Product (CPP) is a crucial requirement for pharmaceutical companies seeking to export their products from the European Union (EU) to international markets. This certification serves as a validation of the pharmaceutical product's compliance with EU and global standards, ensuring its acceptance in markets beyond the EU borders. This section provides a comprehensive overview of the CPP acquisition process, outlining the necessary steps, documentation requirements, and strategic considerations for pharmaceutical exporters.
The Significance of the CPP:
The CPP serves as official proof that a pharmaceutical product authorized for sale in an EU member state meets the Good Manufacturing Practice (GMP) standards set by the EU and aligns with the WHO's format for such certifications. It provides assurance to the importing country that the product has been evaluated and approved by an EU regulatory authority and is legally authorized for marketing within the EU.
Guidelines for Obtaining a CPP:
Ensure that the pharmaceutical product holds a valid marketing authorization in an EU member state. Only products legally approved for sale within the EU are eligible for a CPP.
Application through the National Competent Authority (NCA):
Submit the CPP application to the NCA of the country where the product is manufactured or where the marketing authorization holder is located. Each NCA may have specific application forms and submission procedures.
Provide Comprehensive Product Information:
Include detailed information about the product in the application, such as:
- Trade name and generic name.
- Dosage form and strength.
- Composition details.
- Marketing authorization number and issuance date.
- GMP status of the product.
- Any conditions or restrictions imposed by the regulatory authority.
Compliance with GMP Requirements:
Before issuing a CPP, the EU authority conducts an inspection of the manufacturing facility to ensure compliance with GMP standards. A valid EU GMP certificate is typically required.
Submission of Required Documentation:
The application should include essential documentation, such as:
- Copy of the marketing authorization.
- GMP certificate for the manufacturing site.
- Information on any suspensions or revocations of the product's marketing authorization.
- Authorization for releasing the CPP to a third party, if applicable.
Payment of Applicable Fees:
Most NCAs charge fees for issuing a CPP. It is necessary to comply with the NCA's fee payment guidelines before the certificate can be granted.
Assessment and Issuance Process:
Once the application is submitted, the NCA assesses it based on the established criteria. If all requirements are met, the CPP is issued. The timeline for issuance may vary, so it is advisable to apply well in advance of the intended export date.
In some cases, the importing country may require the CPP to be legalized or apostilled to verify its authenticity. This validation process involves additional steps, such as verification by the foreign ministry or embassy of the importing country.
The acquisition of a Certificate of Pharmaceutical Product is an essential step for EU-based pharmaceutical companies aiming to export their products globally. This certification ensures compliance with international standards and regulatory requirements, facilitating market entry in non-EU countries. By following the guidelines and procedures for CPP acquisition, pharmaceutical exporters can effectively navigate the process, expanding their reach into international markets while upholding the stringent quality and safety standards of the European Union.
Author: Pooyan Ghamari, Swiss Economist & Visionary